Alzheimers Research & Therapy

Article	Citations
A novel electric field approach for improving cognitive function through ameliorating cell-specific pathology in P301S tauopathy mice	261
A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer’s disease	257
Associations of adherence to a healthy sleep pattern with the dementia risk in the UK biobank	189
Recent molecular insights and biosensor-based diagnostic technologies for hyperphosphorylated Tau in Alzheimer's disease	179
Correction: 18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis	172
Longitudinal evaluation of common and unique brain-networks in variants of primary progressive aphasia	166
Development of a Japanese polygenic risk score model for amyloid-β PET imaging in Alzheimer’s disease	156
Anti-tau VHH therapy against PHF6: a safe approach to slowing the phenotype of tau pathology	138
Linking eye movements, pupil responses, and brain networks in early cognitive decline	133
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms	131
Impact of gender on the willingness to participate in clinical trials and undergo related procedures in individuals from an Alzheimer’s prevention research cohort	128
An association of CSF apolipoprotein E glycosylation and amyloid-beta 42 in individuals who carry the APOE4 allele	126
Moderating role of executive function in the relationship between specific white matter changes and long-term delayed recall in aMCI patients	115
Prominent tauopathy and intracellular β-amyloid accumulation triggered by genetic deletion of cathepsin D: implications for Alzheimer disease pathogenesis	110
Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients	109
Diagnostic performance of verbal fluency measures: a cross-sectional study in the stages of cognitive continuum	109
Structural brain improvements following individually tailored serious exergame-based training in mild neurocognitive disorders: exploratory randomized controlled trial	101
Association of modifiable risk factors with progression to dementia in relation to amyloid and tau pathology	100
Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy	98
Greater baseline cortical atrophy in the dorsal attention network predicts faster clinical decline in Posterior Cortical Atrophy	95
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects wi	95
Global and domain-specific cognitive intraindividual variability associations with neurodegenerative diagnoses and postmortem pathologies	90
Stress-induced alteration of small extracellular vesicles drives amyloid-beta sequestration and exacerbates Alzheimer’s disease pathogenesis	85
Amyloid-β PET scans, economic strain and financial decision-making among persons with cognitive impairment and care partners: a mixed-methods analysis of the CARE-IDEAS study	82
ISX9 activates the Wnt/β-catenin signaling pathway and exerts neuroprotective effects in Alzheimer’s disease	77

Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis	76
Investigating the Aβ and tau pathology in autosomal dominant Alzheimer’s disease: insights from hybrid PET/MRI and network mapping	74
Genetic and clinical landscape of Chinese frontotemporal dementia: dominance of TBK1 and OPTN mutations	70
Association between antemortem plasma and structural MRI biomarkers and postmortem tau pathology in the Mayo Clinic Study of Aging	69
High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for Alzheimer’s disease	67
Linking oxysterols and different stages of mild cognitive impairment: insights from gut metabolites and N6-methyladenosine	66
Fluid biomarkers for neurodegenerative diseases: a comprehensive update	66
Granulovacuolar degeneration bodies are independently induced by tau and α-synuclein pathology	65
The economic burden of subjective cognitive decline, mild cognitive impairment and Alzheimer's dementia: excess costs and associated clinical and risk factors	64
Cornuside alleviates cognitive impairments induced by Aβ1−42 through attenuating NLRP3-mediated neurotoxicity by promoting mitophagy	63
Meprin-β levels are increased in the brain and the cerebrospinal fluid of Alzheimer’s disease patients	60
Impact of effective connectivity within the Papez circuit on episodic memory: moderation by perivascular space function	59
Automated high-throughput quantification of plasma p-tau217 and APOE-ε4 for Alzheimer’s disease diagnosis and cognitive decline in a memory cohort	59
Tau seeding activity in the cerebrospinal fluid of Alzheimer disease patients predicts short-term cognitive decline	58
Correction: Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study	57
Functional gradients of the medial parietal cortex in a healthy cohort with family history of sporadic Alzheimer’s disease	54
Mapping the long-term delayed recall-based cortex-hippocampus network constrained by the structural and functional connectome: a case-control multimodal MRI study	54
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the AppNL−F/NL−F knock-in mouse model of Alzheimer’s disease	53
Health-related quality of life in subjective cognitive decline and mild cognitive impairment: a longitudinal cohort analysis	53
Palmitoylation of death receptor p75NTR contributes to Alzheimer’s disease progression by regulating APP trafficking and degradation	51
Hormone therapy is associated with lower Alzheimer’s disease tau biomarkers in post-menopausal females -evidence from two independent cohorts	51
Identification of methylation-regulated genes modulating microglial phagocytosis in hyperhomocysteinemia-exacerbated Alzheimer’s disease	51
The age-specific comorbidity burden of mild cognitive impairment: a US claims database study	50
CEST imaging combined with 1H-MRS reveal the neuroprotective effects of riluzole by improving neurotransmitter imbalances in Alzheimer’s disease mice	49
Genome-wide association studies of Alzheimer’s disease and related disorders stratified by sex, onset age, and Apolipoprotein E genotype reveal novel risk loci in African Americans	49
Real—world application of lecanemab in early—stage alzheimer's disease: a single—center prospective cohort analysis	47
Reduced plasma TIA-1: bridging established pathology and novel biomarker potential	47
A probabilistic framework for clinicopathological Alzheimer’s disease using tau-PET	46
Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC	45
Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease	45
Digital Clock and Recall is superior to the Mini-Mental State Examination for the detection of mild cognitive impairment and mild dementia	42
Longitudinal plasma p-tau217 as a marker for tracking progression and predicting cognitive decline in Alzheimer’s disease	42
The role of structural and functional parameters in designing pathology-specific tDCS protocols for primary progressive aphasia	41
Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease	41
Analytical and clinical performance of eight Simoa® and Lumipulse® assays for automated measurement of plasma p-tau181 and p-tau217	41
Seven tesla MRI reveals amygdala and hippocampal subfield atrophy in dementia with Lewy bodies	41
Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients	41
International consensus for the assessment of social cognition in neurocognitive disorders: framework definition and clinical recommendations of the SIGNATURE initiative	40
Generalizable MRI normative modelling to detect age-inappropriate neurodegeneration	40
Real-world diagnostic performance of blood-based biomarkers for Alzheimer’s disease: robust performance except after stroke and high charlson comorbidity index	40
Readthrough isoform of aquaporin-4 (AQP4) as a therapeutic target for Alzheimer’s disease and other proteinopathies	40
Elevated Aβ aggregates in feces from Alzheimer’s disease patients: a proof-of-concept study	40
Dynamic network model reveals distinct tau spreading patterns in early- and late-onset Alzheimer disease	40
Autonomic and neurosensory disorders in dementia with lewy bodies: prevalence and neural basis in the AlphaLewyMA cohort	40
Polygenic pathways shape white matter vulnerability to Alzheimer’s disease-related pathophysiological changes	40
Diffusion tensor imaging analysis along the perivascular space suggests impaired glymphatic clearance in Lewy body dementia subtypes	40
Interpretable machine-learning prediction of PSEN1 missense variant pathogenicity based on multi-omics enrichment in six core Alzheimer’s disease genes	39
Association between ATN profiles and mortality in a clinical cohort of patients with cognitive disorders	39
Correction: Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non‑rapidly progressive Alzheimer’s disease	38
Sex-specific risk factors and clinical dementia outcomes for white matter hyperintensities in a large South Korean cohort	38

Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer’s disease	38
Characterization of preclinical Alzheimer’s disease model: spontaneous type 2 diabetic cynomolgus monkeys with systemic pro-inflammation, positive biomarkers and developing AD-like pathology	38
Polypharmacy in people with dementia: a nationwide Danish study	37
Ap1s1 reduction in the aging brain heightens neuronal vulnerability to amyloid-β and oxidative stress in Alzheimer’s pathogenesis	37
Subjective cognitive complaints and blood biomarkers of neurodegenerative diseases: a longitudinal cohort study	37
Impact of Apolipoprotein E4 on blood-brain barrier integrity in target replacement murine models: a systematic review and meta-analysis	37
Cross-cultural effects of reminiscence therapy on life satisfaction and autobiographical memory of older adults: a pilot study across Mexico and Spain	37
The autocrine motility factor receptor delays the pathological progression of Alzheimer’s disease via regulating the ubiquitination-mediated degradation of APP	36
The interrelationships of CSF sTREM2, AD pathology, minimal depressive symptoms, and cognition in non-demented adults	36
Olfactory radiomics signatures link pTau217 to cognitive impairment in probable Alzheimer’s disease: a multi-cohort machine learning study	36
Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer’s disease	35
Choroid plexus volume as a novel candidate neuroimaging marker of the Alzheimer’s continuum	35
Disruption of electrophysiological rhythms and memory impairment in an Alzheimer’s transgenic rat model	35
Head-to-head comparison of tau PET tracers [18F]PI-2620 and [18F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort	35
The identification and cognitive correlation of perfusion patterns measured with arterial spin labeling MRI in Alzheimer’s disease	35
An improved immunoassay detects Aβ oligomers in human biofluids: their CSF levels rise with tau and phosphotau levels	35
Divergent brain regional atrophy and associated fiber disruption in amnestic and non-amnestic MCI	35
Quantification of identifying cognitive impairment using olfactory-stimulated functional near-infrared spectroscopy with machine learning: a post hoc analysis of a diagnostic trial and validation of a	34
EEG biomarkers can predict early-stage Alzheimer’s disease and correlate with intracerebral pathology: a multimodal machine learning study	34
Associations between different tau-PET patterns and longitudinal atrophy in the Alzheimer’s disease continuum: biological and methodological perspectives from disease heterogeneity	34
Plasma trimethylamine N-oxide (TMAO): associations with cognition, neuroimaging, and dementia	34
CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease	34
Detecting limbic predominant neurodegenerative co-pathologies in vivo in Alzheimer’s disease: magnetic resonance imaging markers, cognitive correlates, and prognosis	34
Early visual alterations in individuals at-risk of Alzheimer’s disease: a multidisciplinary approach	34
Perivascular space enlargement accelerates in ageing and Alzheimer’s disease pathology: evidence from a three-year longitudinal multicentre study	34
Association of Alzheimer’s disease biomarkers with malnutrition and altered body composition in cognitively impaired patients: a cross-sectional memory clinic study	33
Longitudinal characteristics of plasma biomarkers in Chinese older adults with Alzheimer’s disease	32
Impact of dose and compliance of antidementia medications on long-term outcomes in Alzheimer’s disease: a nationwide real-world study	32
Shared genetic architecture between Alzheimer’s disease and brain morphology	32
Correction: Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer’s disease	32
The reporting of neuropsychiatric symptoms in electronic health records of individuals with Alzheimer’s disease: a natural language processing study	32
Utility of 18F-Florzolotau PET as a prognostic and monitoring biomarker in a memory clinic cohort	32
Associations of white matter hyperintensity regression and progression with cognitive and structural brain changes: a population-based cohort study	32
Distinct effects of blood pressure parameters on Alzheimer’s and vascular markers in 1,952 Asian individuals without dementia	32
Predicting conversion of brain β-amyloid positivity in amyloid-negative individuals	32
Brain reserve contributes to distinguishing preclinical Alzheimer’s stages 1 and 2	31
Clusters of co-abundant proteins in the brain cortex associated with fronto-temporal lobar degeneration	31
White matter hyperintensities and smaller cortical thickness are associated with neuropsychiatric symptoms in neurodegenerative and cerebrovascular diseases	31
Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer’s pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform	31
Development and assessment of algorithms for predicting brain amyloid positivity in a population without dementia	31
Nanoscale alterations in GABAB receptors and GIRK channel organization on the hippocampus of APP/PS1 mice	31
Genetic validation of ABI3 p.Ser209Phe variant and its effects on early brain pathology in asymptomatic elderly individuals	31
Associations of resting heart rate with incident dementia, cognition, and brain structure: a prospective cohort study of UK biobank	31
Correction: Comorbidities predict institutionalization and mortality in biomarker-confirmed alzheimer’s disease	31
Clinical, neuroimaging, and biomarker profiling of four Alzheimer’s disease pedigrees caused by pathogenic APP variants	31
PACAP–Sirtuin3 alleviates cognitive impairment through autophagy in Alzheimer’s disease	31
Evaluating the diagnostic performance of six plasma biomarkers for Alzheimer’s disease and other neurodegenerative dementias in a large Chinese cohort	30
Rescue of protein dyshomeostasis in hippocampal astrocytes from an Alzheimer’s disease mouse model by stabilizing ER-mitochondrial interactions at a 20 nm distance	30
Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxy	30
Synaptic protein CSF levels relate to memory scores in individuals without dementia	30
Social frailty and its association with cognitive trajectories in older adults: a prospective cohort study	30
Dementia with Lewy bodies and gait neural basis: a cross-sectional study	30
Amyloid PET across the cognitive spectrum in former professional and college American football players: findings from the DIAGNOSE CTE Research Project	30
A longitudinal study on quality of life along the spectrum of Alzheimer’s disease	30
Selective agonism of GPR34 stimulates microglial uptake and clearance of amyloid β fibrils	29
Centiloid values from deep learning-based CT parcellation: a valid alternative to freesurfer	29
Cognitive decline profiles associated with lewy pathology in the context of Alzheimer’s disease neuropathologic change	29
18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis	29
Alzheimer’s and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline	29
The associations of herpes simplex virus and varicella zoster virus infection with dementia: a nationwide retrospective cohort study	29
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disea	28
Relationships of change in Clinical Dementia Rating (CDR) on patient outcomes and probability of progression: observational analysis	28
Association of midlife body-weight variability and cycles with earlier dementia onset: a nationwide cohort study	28
A new paradigm for stratified cognitive assessment: fusing serum Raman spectroscopy and ensemble learning	28
Letter to the Editor Authors’ Response: Choroid and choriocapillaris changes in early-stage Parkinson’s disease: a swept-source optical coherence tomography angiography-based cross-sectional study	28
Multi-omics analyses identify gut microbiota-fecal metabolites-brain-cognition pathways in the Alzheimer’s disease continuum	28
REM sleep is associated with the volume of the cholinergic basal forebrain in aMCI individuals	27
Adiponectin deficiency drives cerebrovascular dysfunction and synergizes with amyloid-β to exacerbate alzheimer’s pathology	27
Prediction of conversion from mild cognitive impairment to Alzheimer’s disease and simultaneous feature selection and grouping using Medicaid claim data	27
Impact of appendicular skeletal muscle mass on Alzheimer’s disease in relation to age and comorbidities: an 8-year longitudinal follow-up study of a nationwide cohort	27
Long-term impact of disclosing amyloid PET results to individuals with subjective cognitive decline	27
Towards a national registry for Alzheimer’s disease and related dementias: rationale, design, and initial observations of the ABOARD cohort	27
Italian adaptation of the Uniform Data Set Neuropsychological Test Battery (I-UDSNB 1.0): development and normative data	27
Potential role of Amyloid-β on the association between Orexin-A and blood-brain barrier leakage of globus pallidus in Alzheimer’s disease and dementia with lewy bodies	27
Cognitive impairment indicator for the neuropsychological test batteries in the Canadian Longitudinal Study on Aging: definition and evidence for validity	27
Quantitative estimate of cognitive resilience and its medical and genetic associations	27
How does apolipoprotein E genotype influence the relationship between physical activity and Alzheimer’s disease risk? A novel integrative model	26
Response to Xing et al.: post-marketing safety concerns with Lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database	26
Plasma biomarkers for early detection of alzheimer’s disease: a cross-sectional study in a Japanese cohort	26
Structural and molecular determinants of medial temporal lobe network vulnerability in aging and Alzheimer’s disease	26

Disruption of early visual processing in amyloid-positive healthy individuals and mild cognitive impairment	26
A longitudinal study of the 5xFAD mouse retina delineates Amyloid beta (Aβ)-mediated retinal pathology from age-related changes	26
Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients	26
Influence of co-pathology on CSF and plasma synaptic markers SNAP25 and VAMP2 in Alzheimer’s disease and Parkinson’s disease	26
Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease	26
Neuron-derived extracellular vesicles in blood reveal effects of exercise in Alzheimer’s disease	26
Association of Alzheimer’s disease polygenic risk scores with amyloid accumulation in cognitively intact older adults	25
How healthy participants value additional diagnostic testing with amyloid-PET in patients diagnosed with mild cognitive impairment — a bidding game experiment	25
The role of type 2 diabetes in the association between habitual glucosamine use and dementia: a prospective cohort study	25
Communication about diagnosis, prognosis, and prevention in the memory clinic: perspectives of European memory clinic professionals	25
First-in-human study of neuron regenerative therapy NNI-362 to evaluate the safety, pharmacokinetics, and pharmacodynamics in healthy aged population	25
Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy	25
Multi-omics analysis reveals the key factors involved in the severity of the Alzheimer’s disease	25
Longitudinal resting-state EEG in amyloid-positive patients along the Alzheimer’s disease continuum: considerations for clinical trials	25
Correction: Reduction of NgR in perforant path decreases amyloid-β peptide production and ameliorates synaptic and cognitive deficits in APP/PS1 mice	25
When Alzheimer’s pathology meets cardiometabolic risk: intrinsic subcortical–cortical connectivity signatures of retroactive interference in aging	24
A polygenic risk score for Alzheimer’s disease constructed using APOE-region variants has stronger association than APOE alleles with mild cognitive impairment in Hispanic/Latino adults in the U.S.	24
Association between self-reported poor oral health and subjective cognitive decline: a cross-sectional analysis of US survey data	24
Outer nuclear layer thinning as an in vivo biomarker for discriminating probable FTLD-tau from probable FTLD-TDP with PET-supported subtyping	24
Speech digital biomarker combined with fluid biomarkers predict cognitive impairment through machine learning	24
Income dynamics and risk of early-onset dementia: a nationwide cohort study	24
Reference intervals for plasma amyloid-β, total tau, and phosphorylated tau181 in healthy elderly Chinese individuals without cognitive impairment	24
Long-term retrieval performance is associated with CA1 hippocampal volume in older adults and individuals at risk for dementia	24
Alteration of medial temporal lobe metabolism related to Alzheimer’s disease and dementia with lewy bodies	24
Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer’s disease pathology	24
Neuronal transcriptome, tau and synapse loss in Alzheimer’s knock-in mice require prion protein	24
Development and validation of a novel panel of CSF biomarkers for Alzheimer’s disease	24
Purpose in life promotes resilience to age-related brain burden in middle-aged adults	24
Real-world safety and implementation challenges of lecanemab therapy for Alzheimer’s disease in South Korea: a single-center experience	24
Efficacy and safety of N-acetylcysteine in patients with mild cognitive impairment undergoing exercise-based cardiac rehabilitation program: a randomized controlled trial	23
Altered basal forebrain function during whole-brain network activity at pre- and early-plaque stages of Alzheimer’s disease in TgF344-AD rats	23
Neurodegenerative biomarkers in different chambers of the eye relative to plasma: an agreement validation study	23
Lipidomics profiling reveals distinct patterns of plasma sphingolipid alterations in Alzheimer’s disease and vascular dementia	23
Correction: Photobiomodulation mitigates blood–brain barrier disruption in APP/PS1 mouse model of Alzheimer’s disease by activating the AMPK pathway	23
Methodological quality of systematic reviews on treatments for Alzheimer’s disease: a cross-sectional study	23
Sex differences in Alzheimer’s disease CSF biomarkers and their association with Aβ pathology on PET in cognitively unimpaired individuals	23
An accessible and efficient mobile eye-tracking application for community-based cognitive impairment screening in China	23
Correction: Impact of cumulative exposure to anticholinergic and sedative drugs on cognition in older adults: a memory clinic cohort study	23
Circular RNA APP contributes to Alzheimer’s disease pathogenesis by modulating microglial polarization via miR-1906/CLIC1 axis	23
Altered temporal dynamics of prefrontal ERP responses reflecting neural adaptation in patients with amnestic mild cognitive impairment	23
Fibre density and cross-section associate with hallmark pathology in early Alzheimer’s disease	23
Restless leg syndrome and risk of all-cause dementia: a nationwide retrospective cohort study	22
In vivo evidence for soluble Aβ oligomer-driven neuronal metabolic dysfunction in 5xFAD mice	22
Alzheimer’s polygenic risk scores, APOE, Alzheimer’s disease risk, and dementia-related blood biomarker levels in a population-based cohort study followed over 17 years	22
Diabetes status, duration, and risk of dementia among ischemic stroke patients	22
Small vessel cerebrovascular disease is associated with cognition in prospective Alzheimer’s clinical trial participants	22
Anticipatory reaching motor behavior characterizes patients within the Alzheimer’s disease continuum in a virtual reality environment	22
The effects of a moderate physical activity intervention on physical fitness and cognition in healthy elderly with low levels of physical activity: a randomized controlled trial	22
Novel CSF β-synuclein-specific assays signal early synaptic degeneration in Alzheimer’s disease	22
Double cutoff strategies for plasma pTau217 to predict Tau PET positivity across multiple assay platforms: Tau-enriched and Tau-scarce cohorts for cost-effective clinical use	22
The presence of circulating human apolipoprotein J reduces the occurrence of cerebral microbleeds in a transgenic mouse model with cerebral amyloid angiopathy	22
Optimizing midlife metabolic syndrome thresholds for dementia: a prospective study of two UK population-based cohorts	22
Exploring sex differences in Alzheimer’s disease: a comprehensive analysis of a large patient cohort from a memory unit	22
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217	21
Frontotemporal structure preservation underlies the protective effect of lifetime intellectual cognitive reserve on cognition in the elderly	21
Insomnia, early and late rising are associated with small hippocampal volume and large white matter hyperintensity burden	21
Soluble SorLA in CSF, a novel biomarker to explore disrupted trafficking of SorLA protein in Alzheimer disease	21
Genome-wide association study and polygenic risk scores of retinal thickness across the cognitive continuum: data from the NORFACE cohort	21
Secular trends in incidence, survival, and health status at diagnosis of dementia in Sweden, 2007–2022	21
Sex and APOE ε4 genotype modify risk factor associations with cerebral amyloid angiopathy: a multi-cohort autopsy study	21
Correction: Italian adaptation of the Uniform Data Set Neuropsychological Test Battery (I‑UDSNB 1.0): development and normative data	21
Diagnostic performance of automated plasma amyloid-β assays combined with pre-analytical immunoprecipitation	21
Neurobiological correlates of Mild Behavioral Impairment: a systematic review and meta-analysis	21
Cerebrospinal fluid α-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults	21
Longitudinal validation of cognitive reserve proxy measures: a cohort study in a rural Chinese community	21
Proteomic analysis in Alzheimer’s disease and other dementias: a focus on sex-specific differences	21
Recruitment across two decades of NIH-funded Alzheimer’s disease clinical trials	21
Correction: Short‑term variability of Alzheimer’s disease plasma biomarkers in a mixed memory clinic cohort	21
Correction: Abdominal obesity and the risk of young-onset dementia in women: a nationwide cohort study	21
Human in vivo evidence of associations between herpes simplex virus and cerebral amyloid-beta load in normal aging	21
Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly	21
Age of onset moderates the effects of Vascular Risk Factors on Neurodegeneration, Blood-Brain-Barrier permeability, and cognitive decline in Alzheimer’s Disease	21
Molecular insights into sex-specific metabolic alterations in Alzheimer’s mouse brain using multi-omics approach	21
Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint	20
TNF inhibition differentially impacts regional Abeta immunotherapy efficacy in the humanized hAbSAA mouse model	20
Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns	20
Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer’s disease patients	20
Rationale and design of the BeyeOMARKER study: prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer’s disease pathology in the eye clinic	20
Could tau-PET imaging contribute to a better understanding of the different patterns of clinical progression in Alzheimer’s disease? A 2-year longitudinal study	20
Alzheimer’s disease and cerebrovascular biomarkers in relation to odor identification in a naturalistic clinical cohort	20
Increased levels of GFAP and purinergic P2X7 receptor in Alzheimer’s disease brain are associated with Aβ, tau pathologies and synaptic loss	20
Intermittent hypoxia training enhances Aβ endocytosis by plaque associated microglia via VPS35-dependent TREM2 recycling in murine Alzheimer’s disease	20
Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status	20
NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial	20
Retinal mid-peripheral capillary free zones are enlarged in cognitively unimpaired older adults at high risk for Alzheimer’s disease	20
Network dynamics-based subtyping of Alzheimer’s disease with microglial genetic risk factors	20
Associations of plasma metabolites with protein biomarkers linked to Alzheimer’s disease pathology in the Rotterdam Study	20
Hampered AMPK-ULK1 cascade in Alzheimer’s disease (AD) instigates mitochondria dysfunctions and AD-related alterations which are alleviated by metformin	20
Clinical implications of head trauma in frontotemporal dementia and primary progressive aphasia	20
N, N-Dimethyltryptamine, a natural hallucinogen, ameliorates Alzheimer’s disease by restoring neuronal Sigma-1 receptor-mediated endoplasmic reticulum-mitochondria crosstalk	20
Prevalence of treated patients with Alzheimer’s disease: current trends and COVID-19 impact	20
Is later-life depression a risk factor for Alzheimer’s disease or a prodromal symptom: a study using post-mortem human brain tissue?	20
Biophysical models applied to dementia patients reveal links between geographical origin, gender, disease duration, and loss of neural inhibition	20
Correction: Diagnostic performance of plasma pTau217, pTau181, Aβ1‑42 and Aβ1‑40 in the LUMIPULSE automated platform for the detection of Alzheimer disease	20
The effects of imaging markers on clinical trajectory in cerebral amyloid angiopathy: a longitudinal study in a memory clinic	19